

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

CLARIFICATION ANNOUNCEMENT

Reference is made to the announcement of the Company dated 20 June 2016 in relation to the Investment Agreement (the “**Announcement**”). Capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board wishes to clarify certain information in the Announcement.

Information of the Project Company

The Board wishes to clarify that under the Investment Agreement, the Project Company, upon its establishment, will become an indirect wholly-owned subsidiary of the Company. Hence, the Investment Agreement does not constitute a notifiable transaction under Chapter 14 of the Listing Rules and the Announcement was made pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions.

The Board wishes to further clarify and correct the Announcement as follows:

- (i) The title of the Announcement shall be replaced as:

“INSIDE INFORMATION IN RELATION TO THE INVESTMENT AGREEMENT WITH ZHENJIANG COMMITTEE”

- (ii) The following paragraph of the Announcement:

“This announcement is also made pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions.”

shall be replaced with:

“This announcement is made pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions.”

(iii) The following paragraph of the Announcement shall be deleted in its entirety:

“IMPLICATIONS UNDER THE LISTING RULES

Given that the applicable percentage ratios (as defined under the Listing Rules) in respect of the Investment exceed 5% and all applicable percentage ratios are less than 25%, the investment constitutes a discloseable transaction of the Company under the Listing Rules and is therefore subject to notification and announcement requirements under Chapter 14 of the Listing Rules.”

Save as disclosed above, all other information in the Announcement remains unchanged.

Potential investors and shareholders of the Company are advised to exercise caution when dealing in shares of the Company.

By Order of the Board
Genscript Biotech Corporation
Dr. Zhang Fangliang
Chairman

Hong Kong, 21 June 2016

As at the date of this announcement, our executive Directors are Dr. ZHANG Fangliang, Ms. WANG Ye, and Mr. MENG Jiange; our non-executive Directors are Dr. WANG Luquan, Mr. HUANG Zuie-Chin, and Mr. PAN Yuexin; and our independent non-executive Directors are Mr. GUO Hongxin, Mr. DAI Zumian, and Ms. ZHANG Min.

* *For identification purposes only*